<< Back To Search

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
We want to see how well a medicine called Descartes-08 works for people with a type of cancer called high-risk myeloma. We want to know if it can get rid of the leftover cancer cells after their first treatment. We call it Minimal Residual Disease-negative Complete Response.
*Third Opinion AI Generated Synopsis

Trial Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?